Filtered By:
Condition: Atrial Fibrillation
Management: Hospitals
This page shows you your search results in order of date. This is page number 14.
Order by Relevance | Date
Total 621 results found since Jan 2013.
Determinants of atrial fibrillation after cardiac surgery
Rev Cardiovasc Med. 2021 Jun 30;22(2):329-341. doi: 10.31083/j.rcm2202040.ABSTRACTPost-operative Atrial fibrillation (POAF) is a common complication post cardiac surgery. It can result in detrimental short- and long-term outcomes due to the increased risk of stroke, cardiac arrest and congestive heart failure in addition to prolonged intensive care and total hospital stay raising the overall healthcare cost. Accurately identifying predictors and biomarkers for POAF ensures that patients at greatest risk can be given the appropriate prophylactic measures; resources can be distributed to the groups who are most in need and w...
Source: Reviews in Cardiovascular Medicine - July 14, 2021 Category: Cardiology Authors: Mashal Qureshi Ammaarah Ahmed Victoria Massie Ellenor Marshall Amer Harky Source Type: research
The incidence of stroke in patients with early echocardiography after acute myocardial infarction
AbstractLeft ventricular (LV) thrombus formation after ST-elevation myocardial infarction (STEMI) increases the risk of stroke. In our center, most echocardiograms are performed within 2 days post-STEMI. However, LV thrombi often become visible later. We assessed the 1-year incidence of stroke in patients without LV thrombus on echocardiography performed early (1–2 days) vs. later (day ≥ 3) post-STEMI. This retrospective observational study included 416 patients with acut e STEMI. Patients with atrial fibrillation were excluded. All patients underwent echocardiography during admission. Patients with stroke withi...
Source: The International Journal of Cardiovascular Imaging - July 12, 2021 Category: Radiology Source Type: research
Impact of Atrial Fibrillation on In-Hospital Mortality and Stroke in Acute Aortic Syndromes
Acute aortic syndromes may present with a number of cardiovascular complications, including atrial fibrillation. We assessed the prevalence of atrial fibrillation in patients presenting with acute aortic syndromes and evaluated atrial fibrillation's association with in-hospital mortality and stroke.
Source: The American Journal of Medicine - July 6, 2021 Category: General Medicine Authors: Umberto Campia, Samantha M. Rizzo, Julia E. Snyder, Mariana A. Pfefferman, Ruth B. Morrison, Gregory Piazza, Samuel Z. Goldhaber Source Type: research
Reflux esophagitis is associated with higher risks of acute stroke and transient ischemic attacks in patients hospitalized with atrial fibrillation: A nationwide inpatient sample analysis
Reflux esophagitis (RE) is a subset of gastroesophageal reflux disease (GERD) with endoscopic evidence of esophageal inflammation, which has been linked to an increased incidence of atrial fibrillation (AF). However, data on the effect of RE on patient outcomes is limited. We sought to examine the potential association of RE with outcomes of patients with AF in a nationwide study.
The National Inpatient Sample (NIS) database was queried to identify hospitalized adult patients with AF and RE between 2010 and 2014. Primary outcomes included inpatient mortality, length of stay (LOS), and total hospital charges. AF related ...
Source: Medicine - June 25, 2021 Category: Internal Medicine Tags: Research Article: Observational Study Source Type: research
Janssen Submits New Drug Application to U.S. FDA for XARELTO ® (rivaroxaban) to Help Prevent and Treat Blood Clots in Pediatric Patients
RARITAN, NJ, June 23, 2021 – The Janssen Pharmaceutical Companies of Johnson & Johnson announced today it has submitted a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for the use of XARELTO® (rivaroxaban) in pediatric patients. The NDA seeks two pediatric indications: treatment of venous thromboembolism (VTE, or blood clots) and reduction in the risk of recurrent VTE in patients aged birth to less than 18 years of age after at least five days of initial parenteral anticoagulant treatment; and thromboprophylaxis (prevention of blood clots) in patients aged 2 years and older with congenita...
Source: Johnson and Johnson - June 23, 2021 Category: Pharmaceuticals Tags: Innovation Source Type: news
Commentary: Enhanced Recovery After Cardiac Surgery (ERAS): A rising tide that will lift all boats?
This study used propensity matching to compare outcomes between 76 matched pairs of ERAS cohort patients and non-contemporaneous historical controls. The authors demonstrated significantly shorter ventilation time, intensive care unit (ICU) stay, and post-operative length of stay (LOS) without significant differences in 30-day readmission rates, post-operative stroke, acute kidney injury, atrial fibrillation, reoperation rates for bleeding, or mortality at two years in the ERAS patients.
Source: Seminars in Thoracic and Cardiovascular Surgery - June 15, 2021 Category: Cardiovascular & Thoracic Surgery Authors: Mary E. Huerter, Leora B. Balsam Tags: ADULT – Commentary Source Type: research
